Second, GDF11 H-score: the lower GDF11 H-score in the patients with larger tumor sizes, advanced pathological stages, and specific molecular subtypes of breast cancer (such as luminal B HER2-negative and triple-negative subtypes) implies that GDF11 exerts a potential tumor-suppressive role. Here, ERBB2 is linked to breast carcinoma.